Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Europe Health Technology Assessment Market Access

Firms Told To Get Ready Now For New EU HTA Regulation

  • Analysis

Executive Summary

Comparator selection and joint scientific consultation slots are among top concerns for companies operating in the EU as EUnetHTA 21 consortium preparations for new HTA regulations get going.

You may also be interested in...



European HTA Legislation Clears Final Hurdle

Risk of unpredictable system still real depending on how EU member states approach joint clinical assessments, warns industry.

New EU HTA Consortium Prepares To Launch

Two new groups have been formed in preparation for the application of the EU regulation on health technology assessment cooperation.

Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.

Table

View full table

Topics

Tags:
Europe Health Technology Assessment Market Access
Latest Headlines

Simplified Clinical Trial Transparency Rules To Go Live In The EU In June

Changes To EU Pharma Reform: More Questions Than Answers?

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

See All
UsernamePublicRestriction

Register

PS145434

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By